LFCR (Lifecore Biomedical) Payments of Debt: $-176.60 Mil (TTM As of Mar. 2026)


LFCR Lifecore Biomedical Inc LFCR
55 GF Score
Price $4.86
GF Value $6.50
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Lifecore Biomedical Payments of Debt?

Lifecore Biomedical LFCR -3.67% 55 Payments of Debt is $-176.60 Mil as of Mar. 2026. GuruFocus rates LFCR with a GF Score™ of 55/100 and a GF Value™ of $6.50 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Lifecore Biomedical's Payments of Debt for the three months ended in Mar. 2026 was $-36.40 Mil.

Lifecore Biomedical's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $-176.60 Mil.

Lifecore Biomedical Payments of Debt Related Terms

Lifecore Biomedical Payments of Debt Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Payments of Debt Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -262.53 -174.63 -232.97 -146.70 -145.76

Lifecore Biomedical Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.89 -127.87 -12.33 0.00 -36.40
LFCR
55GF Score
Lifecore Biomedical Inc LFCR
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lifecore Biomedical Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-176.60 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-176.60 Mil mean?
Lifecore Biomedical (LFCR) has a Payments of Debt of $-176.60 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Lifecore Biomedical and its competitors.
Is Lifecore Biomedical's Payments of Debt too high?
Lifecore Biomedical's current Payments of Debt is $-176.60 Mil. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's Payments of Debt compare to ANIK and DERM?
Lifecore Biomedical's Payments of Debt of $-176.60 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Lifecore Biomedical and its competitors. Lifecore Biomedical's current Payments of Debt is $-176.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.50, compared to a current price of $4.86 — trading 25.2% below its estimated fair value. The current Payments of Debt is $-176.60 Mil. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current Payments of Debt is $-176.60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lifecore Biomedical (LFCR) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of $4.86 is trading 25.2% below its estimated GF Value™ of $6.50. GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.

Key valuation signals for LFCR:

  • Payments of Debt: $-176.60 Mil
  • GF Value™: $6.50 vs. price of $4.86 (25.2% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lifecore Biomedical Business Description

Other Exchanges LDE:Germany
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
55GF Score

Get the complete analysis for LFCR

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.86
Price
$6.50
GF Value